We are live on ! Find out more
VRDN icon

Viridian Therapeutics
VRDN

165 hedge funds and large institutions have $1.98B invested in Viridian Therapeutics in 2024 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 66 increasing their positions, 41 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

900% more funds holding in top 10

Funds holding in top 10: 1 → 10 (+9)

175% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 16

118% more capital invested

Capital invested by funds: $906M → $1.98B (+$1.07B)

61% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 41

20% more funds holding

Funds holding: 138 → 165 (+27)

4.75% more ownership

Funds ownership: 109.13% → 113.88% (+4.8%)

8% more call options, than puts

Call options by funds: $13.9M | Put options by funds: $12.9M

Holders
165
Holders Change
+27
Holders Change %
+19.57%
% of All Funds
2.37%
Holding in Top 10
10
Holding in Top 10 Change
+9
Holding in Top 10 Change %
+900%
% of All Funds
0.14%
New
44
Increased
66
Reduced
41
Closed
16
Calls
$13.9M
Puts
$12.9M
Net Calls
+$1.01M
Net Calls Change
+$3.94M

Top Buyers

1
DCM
Driehaus Capital Management
Illinois
+$32.6M
2
EC
EcoR1 Capital
California
+$32M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$26.3M
4
FFM
Fairmount Funds Management
Pennsylvania
+$26.2M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$19.7M

Top Sellers

1
MC
Maverick Capital
Texas
-$21.4M
2
PCH
Polar Capital Holdings
United Kingdom
-$11.6M
3
GTC
Ghost Tree Capital
New York
-$8.38M
4
RI
RTW Investments
New York
-$7.88M
5
State Street
State Street
Massachusetts
-$6.42M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
76
Soleus Capital Management
Connecticut
$2.16M -$4.01M -245,000 -72%
Rafferty Asset Management
77
Rafferty Asset Management
New York
$2.06M -$888K -54,324 -37%
UBS AM
78
UBS AM
Illinois
$2.04M +$330K +20,166 +29%
RhumbLine Advisers
79
RhumbLine Advisers
Massachusetts
$2.01M -$40.6K -2,482 -3%
SFM
80
Sphera Funds Management
Israel
$1.96M +$1.41M +86,094 New
UBS Group
81
UBS Group
Switzerland
$1.93M -$2.38M -145,643 -63%
BC
82
BIT Capital
Germany
$1.91M -$1M -61,410 -42%
Susquehanna International Group
83
Susquehanna International Group
Pennsylvania
$1.73M +$436K +26,698 +54%
GTC
84
Ghost Tree Capital
New York
$1.71M -$8.38M -512,708 -87%
Renaissance Technologies
85
Renaissance Technologies
New York
$1.36M -$3.07M -188,000 -76%
KOCAA
86
Knights of Columbus Asset Advisors
Connecticut
$1.31M -$366K -22,409 -28%
PCM
87
Prelude Capital Management
New York
$1.16M +$835K +51,050 New
CSS
88
Cubist Systematic Strategies
Connecticut
$1.16M +$832K +50,898 New
Legal & General Group
89
Legal & General Group
United Kingdom
$1.12M +$123K +7,536 +18%
Wells Fargo
90
Wells Fargo
California
$1.11M +$189K +11,546 +31%
AA
91
ALPS Advisors
Colorado
$1.07M -$48.1K -2,941 -6%
California State Teachers Retirement System (CalSTRS)
92
California State Teachers Retirement System (CalSTRS)
California
$1.05M -$14K -859 -2%
Citigroup
93
Citigroup
New York
$1.05M +$311K +19,014 +70%
T. Rowe Price Associates
94
T. Rowe Price Associates
Maryland
$1.02M +$9.7K +593 +1%
Squarepoint
95
Squarepoint
New York
$991K -$1.62M -99,357 -70%
Ameriprise
96
Ameriprise
Minnesota
$955K +$343K +21,002 +100%
Group One Trading
97
Group One Trading
Illinois
$927K +$505K +30,898 +313%
Tudor Investment Corp
98
Tudor Investment Corp
Connecticut
$848K +$609K +37,261 New
MIM
99
MetLife Investment Management
New Jersey
$828K – – –
Point72 Asset Management
100
Point72 Asset Management
Connecticut
$788K +$566K +34,627 New
2 3
4
5 6

VRDN Hedge Fund Activity: Q3 2024 in Review

165 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q3 2024, worth a combined $1.98B — up 118% from $906M a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new VRDN positions and 16 closed out — a net gain of 28 holders — while 66 added to existing stakes and 41 trimmed.

The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $32.6M. The largest seller was Maverick Capital, cutting an estimated $21.4M.

  • 165 institutional investors held Viridian Therapeutics (VRDN) as of Q3 2024, up from 138 in Q2 2024.
  • Funds reported $1.98B of Viridian Therapeutics stock for Q3 2024, up 118% quarter-over-quarter.
  • 44 funds opened new Viridian Therapeutics positions in Q3 2024 and 16 closed out, a net change of +28 holders.
  • The largest Viridian Therapeutics buyer in Q3 2024 was Driehaus Capital Management, an estimated $32.6M added.
  • The largest Viridian Therapeutics seller in Q3 2024 was Maverick Capital, an estimated $21.4M sold.

Based on aggregated 13F filings for Q3 2024.